186 results about "Acute Renal Injury" patented technology

The present invention relates to methods and compositions for monitoring, diagnosis, prognosis, and determination of treatment regimens in subjects suffering from or suspected of having a renal injury. In particular, the invention relates to using assays that detect one or more markers selected from the group consisting of soluble p-selectin, protein NOV homolog, soluble epidermal growth factor receptor, netrin-4, haptoglobin, heat shock protein beta-1, alpha-1-antitrypsin, leukocyte elastase, soluble tumor necrosis factor receptor superfamily member 6, soluble tumor necrosis factor ligand superfamily member 6, soluble intercellular adhesion molecule 2, active caspase-3, and soluble platelet endothelial cell adhesion molecule as diagnostic and prognostic biomarkers in renal injuries.

We disclose a new and useful biomarker for acute kidney injury (i.e., AKI), renal ischemia reperfusion injury (i.e., IRI), ischemic acute kidney injury, and/or ischemic acute tubular necrosis (i.e., ATN). The biomarker is GRO-alpha (i.e., CXCL1, chemokine C-X-C ligand 1, GRO1, GROa, MGSA, MGSA alpha, MGSA-a, NAP-3, SCYB1). We detected the biomarker using a QUANTIKINE® human GRO-alpha immunoassay (Cat. No. DGR00, R & D Systems, Minneapolis, Minn.). In addition, we disclose a method of treating lung damage.

The present invention is directed to acute kidney injury biomarkers, and methods and kits comprising the use of agents directed against acute kidney injury biomarkers for facilitating and enhancing the diagnosis of AKI. The present invention is based on the discovery that specific biomarkers are present in urine at higher concentrations in subjects with acute kidney injury (AKI) as compared with subjects that have no symptoms of AKI. The invention is directed to methods for diagnosis of AKI by determining and monitoring the levels of at least one biomarker protein in a biological sample, such as urine. Further, the invention is directed to methods for facilitating the distinction of kidney infection from bladder infection in a subject.

It is an object of the present invention to provide a combination of a functional assessment of renal function together with biomarker results in order to improve assessment of patient at risk of or having, an acute kidney injury. A loop diuretic such as furosemide inhibits luminal active chloride transport throughout the thick ascending limb of Henle, thereby preventing sodium reabsorption and resulting in natriuresis and increased urine flow. Loop diuretic-induced increases in urine output might be a method to assess the integrity of the renal tubular function in the setting of early AKI, and so a kidney's response, or lack thereof, to a diuretic challenge as a clinical assessment of tubular function can identify patients with severe tubular injury before it is clinically apparent (e.g. a rise in creatinine).

The injection preparation for treating acute lung injury and acute respiratory distress syndrome is bacteria-free freeze dried powder for injection with Sivelestat as active component, stuffing frame agent, co-solvent and pH regulator. It has improved water solubility of Sivelestat and improved medicine stability.

The embodiment of the invention discloses an acute kidney injury patient death rate prediction method and device, a server and a storage medium. The method comprises the steps of generating medical feature data of a specific structure according to clinical medical data of a to-be-tested patient; and selecting a corresponding pre-trained random forest model according to the survival state and survival days of the to-be-tested patient, inputting the medical feature data of the to-be-tested patient into the corresponding pre-trained random forest model, and outputting the death rate of the to-be-tested patient. According to the technical scheme of the embodiment of the invention, the death rate of the acute kidney injury patient is predicted through the random forest model, the structured clinical data is used for training, and the logistic regression algorithm is used to calibrate the model, so that fuzzy clinical definition and data acquisition deviation are effectively avoided, and theaccuracy of predicting the death rate of the acute kidney injury patient is improved.

The invention discloses a nano-enzyme diagnosis and treatment agent for acute kidney injury and a preparation method and use of nano-enzyme diagnosis and treatment agent. The nano-enzyme diagnosis andtreatment agent comprises Prussian blue nano-particles and surface ligands combined on surfaces of the Prussian blue nano-particles. The nano-enzyme diagnosis and treatment agent comprises the surface ligands (CS) and the Prussian blue nanoparticles (PB NZs) protected by the surface ligands. The nano-enzyme diagnosis and treatment agent has an ultra-small size, can be effectively enriched in thekidney of a mouse, can remove a large amount of active oxygen or active nitrogen in kidney tubules to relieve and treat acute kidney injury induced by glycerol or cis-platinum, and can be used as a contrast agent for nuclear magnetic resonance imaging and photoacoustic imaging technologies. In addition, the nano-enzyme diagnosis and treatment agent has a good treatment effect and also has excellent biocompatibility and biosafety.

Methods are provided of diagnosing, monitoring or determining the severity of disease or injury by measuring individual molecular forms of neutrophil gelatinase-associated lipocalin (NGAL) in bodily fluids, including the diagnosis and monitoring of acute renal injury leading to acute renal failure in a human or mammalian subject by determining the concentration of the free monomer form of NGAL.

A method for distinguishing between kidney dysfunctions in a mammal, including pre-renal azotemia, an acute renal injury that may progress to acute renal failure, and chronic kidney disease, using a urinary or circulating NGAL assay result that is compared to a predetermined NGAL cutoff level, and a single serum or plasma creatinine measurement. Typically the single creatinine measurement cannot distinguish acute renal injury from chronic kidney disease or pre-renal azotemia, a single measurement of urinary NGAL, combined with the single serum or plasma creatinine measurement, has sufficient sensitivity and specificity to distinguish acute renal injury from normal function, prerenal azotemia, and chronic kidney disease and predicts poor inpatient outcomes. Patients admitted to the emergency department of the hospital with any of acute kidney injury, prerenal azotemia, chronic kidney disease, or even normal kidney function, can be evaluated based on the single measurements of urinary or circulating NGAL, and serum or plasma creatinine. Urinary NGAL level is highly predictive of clinical outcomes, including nephrology consultation, dialysis, and admission to the intensive care unit.

Disclosed herein are compositions and methods for repairing cell membranes. In particular, the description provides compositions and methods comprising MG53, a member of the TRIM-family of proteins, in the repair of kidney injury and its therapeutic use in the prevention and treatment of kidney injury.

The invention discloses application of condonpsis lanceolata extract in preparation of medicine for preventing cisplatin induced acute renal injuries and belongs to the field of medicine product research and development. The animal experiment research shows that compared with a model set, the condonpsis lanceolata extract can effectively reduce the content of creatinine (CRE), urea nitrogen (BUN), inflammatory factors (TNF-alpha) and interleukin 1beta (IL-1beta) in serum and malonaldehyde (MDA) in nephridial tissue; in addition, histopathology shows that the condonpsis lanceolata extract can reduce lesions of the nephridial tissue and reduce apoptosis of nephridial tissue cells; immunohistochemistry shows that the condonpsis lanceolata extract can effectively reduce expression of Bax and increase expression of Bcl-2. Thus, the condonpsis lanceolata extract and effective ingredients containing the extract can be prepared into the medicine or healthcare products for preventing acute renal injuries, the forms of the medicine or the healthcare products can be existing any dosage forms such as tablets, capsules, pills, soft capsules, granules and patches.

The invention discloses use of NSC228155 in the preparation of a medicine for preventing and treating acute kidney injury, and particularly relates to application of NSC228155 for treating acute renalinjury by protecting renal tubular epithelial cells. NSC228155 can improve the renal function of a cis-platinum-induced acute kidney injury mouse model, improve the pathological changes of acute renal tubular injury, reduce the apoptosis of mouse kidney tissue, reduce the inflammatory response of kidney tissue, and improve the cis-platinum-induced mitochondrial function and oxidative stress status of the mouse renal cortex tissues and renal tubular epithelial cells and protect renal tubular epithelial cells.

The invention discloses application of a benzenesulfonamide compound in preparation of a medicine for treating and/or preventing acute kidney injury. The structural formula of the benzenesulfonamide compound is shown in the specification. The acute kidney injury is cisplatin or kidney ischemia reperfusion induced acute kidney injury. Experiments show that through administration of the benzenesulfonamide compound, the levels of BUN and SCr in serum of a mouse with acute kidney injury can be remarkably reduced, and the renal tissue form injury of the mouse with acute kidney injury can be remarkably relieved. The benzenesulfonamide compound has very important value for clinical prevention and treatment of acute kidney injury.

The invention discloses an early warning method and system for acute kidney injury after extracorporeal circulation cardiac surgery. The early warning method comprises the steps: acquiring the preoperative age, the preoperative height, the urea nitrogen level value on the day of surgery and the urine ATF3 level value 12 hours after the surgery of a patient suffering from the extracorporeal circulation cardiac surgery; carrying out dimension normalization on the age before operation, the height before operation, the urea nitrogen level value on the day of operation and the urine ATF3 level value 12 hours after operation; taking the normalized preoperative age, the normalized preoperative height, the normalized urea nitrogen level value on the day of the operation and the normalized urine ATF3 level value 12 hours after the operation as variables, and establishing a disease prediction model of the cardiac postoperative acute kidney injury; and calculating and outputting the incidence prediction probability of the cardiac postoperative acute kidney injury. Independent risk factors (preoperative age, preoperative height, urea nitrogen level value on the day of operation and urine ATF3 level value of 12 hours after operation) of AKI are used as variables to construct an early warning model of acute kidney injury, and the prediction accuracy is high.

The invention provides application of trehalose in preparation of a medicine for relieving renal ischemia-reperfusion injury, and belongs to the field of biological medicines. The application proves that trehalose can alleviate ischemia-reperfusion induced acute kidney injury related diseases, including acute kidney injury renal function, oxidative stress, renal tubular cell apoptosis, renal inflammatory cell infiltration and the like, by enhancing autophagy, thereby providing a theoretical basis for widening the possible application range of trehalose. As trehalose has been approved to be a safe food component by American Food and Drug Administration at present and has been applied to food preservation and other work, it is found that effective clinical drugs are extremely likely to be provided for prevention and treatment of AKI.

The invention discloses application of a phospholipid polyethylene glycol modified subminiature cerium oxide nano-enzyme in preparation of a medicine for treating acute kidney injury. The acute kidneyinjury is induced by cis-platinum when cis-platinum is used for treating solid cancer. The phospholipid polyethylene glycol modified subminiature cerium oxide nano-enzyme provided by the invention can present activities of various antioxidant mimic enzymes, can play an efficient catalase activity in a physiological environment, effectively reduces the ROS level by acting on an Nrf2/Keap1 pathway,inhibits cell apoptosis, exerts important protection and treatment effects on acute kidney injury caused by cis-platinum, and is a more promising nanomaterial for low-toxicity anti-tumor applicationand development cis-platinum in clinical practice.

The invention discloses an application of mPGES-2 as a drug target for preventing and/or treating kidney diseases. The invention proposes that the mPGES-2 is the cis-platinum-induced acute kidney injury drug target for the first time. Experiments show that mPGES-2 knockout can significantly reduce the levels of urea nitrogen and creatinine in the serum of a mouse with cis-platinum-induced acute kidney injury, significantly reduce the renal tissue form injury of the mouse with the cis-platinum-induced acute kidney injury and significantly improve the mitochondrial function in the kidneys of the mouse with acute kidney injury and reduce cell apoptosis. The results show that the cis-platinum-induced acute kidney injury can be reduced by mPGES-2 knockout, so that the mPGES-2 can be used as the target for preventing and/or treating the cis-platinum-induced acute kidney injury, and the mPGES-2 has very important significance on drug development and prevention and/or treatment of the diseases in the future.

The invention discloses application of Wnt4 used as an early biomarker of acute kidney injury in detecting early acute kidney injury. Animal experiments and clinical experiments prove that the acute kidney injury early detection biomarker Wnt4, provided by the invention, starts to rise in an early expression of acute kidney injury rats; in patients with clinical MCD combined renal tubular injury, when serum creatinine does not start to rise yet, a Wnt4 expression is remarkably increased at the injured renal tubule part, and is positively correlated with a renal tubular injury degree, so that the Wnt4 is reminded to be used as the early, non-traumatic and sensitive biomarker for detecting renal tubular injury and used for early detecting the acute kidney injury. The invention provides a novel non-traumatic acute kidney injury detection method, which is of great significance on early diagnosis and prognosis evaluation of diseases.

The invention discloses an application of ginsenoside Rg5 (C42H70O12, CAS (chemical abstracts service) No. 186763-78-0) in preparation of a drug for preventing CDDP (cis-diamine dichloroplatinum) induced acute kidney injury, and belongs to the field of research and development of medical products. Animal studies show that compared with a module group, ginsenoside Rg5 can reduce the levels of Cre (creatinine) and BUN (blood urea nitrogen) in serum effectively and increase the levels of SOD (superoxide dismutase) and GSH (glutathione) in kidney tissue; besides, ginsenoside Rg5 can obviously inhibit increase of inflammatory factors such as TNF (tumor necrosis factor)-alpha and IL (interleukin)-1beta in the kidney tissue. Therefore, the drug for preventing the acute kidney injury can be prepared from ginsenoside Rg5 and effective ingredients of ginsenoside Rg5. The drug form can adopts any existing dosage forms such as tablets, capsules, powder injections, injections, pills, soft capsules, granules, patches and the like.

The present invention is directed to methods of treating a human patient with acute kidney injury.

The invention discloses application of eurycomanone in preparation of a medicine for preventing and treating acute kidney injury, and belongs to the field of biomedicines. According to the invention,animal in-vivo research finds that eurycoma longifolia extract and the eurycomanone can effectively relieve acute renal function decline and renal tissue injury of mice due to ischemia-reperfusion injury. The eurycomanone is a main active ingredient in eurycoma longifolia. In-vivo and in-vitro studies find that the eurycomanone protects the mitochondrial function by activating an AMPK/PGC-1[alpha]signal path, so that renal inflammatory response mediated by proximal renal tubular epithelial cell injury is relieved. Therefore, the eurycoma longifolia aqueous extract and the eurycomanone have anobvious kidney protection effect, do not have lethal toxic and side effects, and can be used for preparing acute kidney injury resisting medicines.